Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.36 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.35 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | FABP6 | P51161 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203198 | 0.82 | ALDH1A1 (0.43) | KDM1AUSP30FABP6NSD2HTR1A | |
| SCHEMBL3309811 | 0.79 | SMYD3 (0.36) | SMYD3HTR2AHTR2CKDM1AUSP30 | |
| SCHEMBL15226092 | 0.75 | CA1 (0.47) | MCOLN2MCOLN1POLBKMT2A | |
| SCHEMBL4193315 | 0.74 | SMYD3 (0.39) | SMYD3HTR2AHTR2CPOLBHTR6 | |
| SCHEMBL3310495 | 0.73 | MC4R (0.58) | POLBKMT2A | |
| SCHEMBL799013 | 0.71 | CA12 (0.39) | HTR2APOLB | |
| SCHEMBL18559454 | 0.71 | CA12 (0.39) | SMYD3HTR2AHTR2CKDM1AUSP30 | |
| SCHEMBL5245677 | 0.71 | MCOLN2 (0.61) | HTR2AHTR2CUSP30MCOLN2MCOLN1 | |
| Bicarbonate SCHEMBL15226056 | 0.71 | KDM4E (0.50) | MCOLN2MCOLN1KMT2A | |
| SCHEMBL13621192 | 0.70 | CA1 (0.56) | SMYD3HTR2AHTR2CKDM1AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | SMYD3 4052/4885HTR2A 4343/4885HTR2C 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.